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ABSTRACT
The deacetylase inhibitor Trichostatin A (TSA)
induces the transcription of the Major Histocom-
patibilityClassII(MHCII)DRAgeneinawayindepend-
ent of the master coactivator CIITA. To analyze the
molecular mechanisms by which this epigenetic
regulator stimulates MHC II expression, we used
chromatin immunoprecipitation (ChIP) assays to
monitor the alterations in histone modifications that
correlate with DRA transcription after TSA treatment.
We found that a dramatic increase in promoter
linked histone acetylation is followed by an increase
in Histone H3 lysine 4 methylation and a decrease of
lysine 9 methylation. Fluorescence recovery after
photobleaching (FRAP) experiments showed that
TSAincreasesthemobilityofHDACwhiledecreasing
themobilityoftheclassIIenhanceosomefactorRFX5.
These data, in combination with ChIP experiments,
indicate that the TSA-mediated induction of DRA
transcription involves HDAC relocation and enhan-
ceosome stabilization. In order to gain a genome-
wide view of the genes responding to inhibition of
deacetylases, we compared the transcriptome of B
cells before and after TSA treatment using
Affymetrix microarrays. This analysis showed that
in addition to the DRA gene, the entire MHC II family
and the adjacent histone cluster that are located in
chromosome 6p21-22 locus are strongly induced by
TSA. A complex pattern of gene reprogramming by
TSAinvolvesimmunerecognition,antiviral,apoptotic
andinflammatorypathwaysandextendstherationale
for using Histone Deacetylase Inhibitors (HDACi) to
modulate the immune response.
INTRODUCTION
Epigenetic mechanisms of gene expression are important for
cell function and homeostasis (1). Histone Deacetylase Inhib-
itors (HDACi) such as Trichostatin A (TSA), butyric acid
and SAHA, are epigenetic chemicals that modulate gene
expression and thus affect cell proliferation, differentiation
and apoptosis. The above actions, in combination with their
tumor-selectivity make HDACi promising molecules for can-
cer treatment that are currently under phase I and II trials.
Products of the Major Histocompatibility Class II (MHC II)
genes present antigenic peptides to T cells and are critical for
the speciﬁcity and efﬁciency of the immune response. Increas-
ingevidenceshowsthatMHCIIproductsalsocontributetothe
recognition of tumor cells by CD4+ T cells and anti-tumor
immunity. MHC II expression (2) relies on the constitutive or
cytokine induced synthesis of the master regulator Class II
Transactivator (CIITA) (3).
Many reports have established the importance of histone
acetylationaspositiveregulatorofMHCIItranscription(4–6).
The interaction of CIITA with various Histone Acetylases
(HATs) such as CBP (7,8), PCAF (9) and SRC-1 (10) was
*To whom correspondence should be addressed. Tel: +30 2810 391165; Fax: +30 2810 391101; Email: papamath@imbb.forth.gr
  The Author 2006. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Nucleic Acids Research, 2006, Vol. 34, No. 3 765–772
doi:10.1093/nar/gkj462linked to MHC II gene activation. Interestingly, CIITA also
interacts with HDACs and may act as a molecular switch
between opposing chromatin regulators (11,12). CIITA dele-
tions or epigenetic silencing during development and in
tumors eliminate MHC II expression (13). A yet unexplored
issue is the regulation of MHC II transcription without CIITA.
CIITA knock out mice have residual MHC II expression in
certain cell types (14,15) and CIITA independent induction of
MHC II in epithelial cells was also reported (16).
To investigate if histone acetylation promotes MHC II
transcription independently of CIITA, we used TSA to
treat the CIITA mutant line RJ 225 (17) as reported previously
(18). We show that the transcriptional activation of the
MHC II DRA gene by TSA is linked to promoter hyperac-
etylation and an increase of H3 lysine 4 methylation and a
decrease of lysine 9 methylation. TSA-mediated transcription
correlates with increased mobility of HDACs and reduced
mobility of the RFX5 enhanceosome factor. Gene proﬁling
of RJ225 before and after TSA treatment using Affymetrix
microarrays reveals diverse groups of genes that are regulated
by TSA. Many members of the MHC II and the Hist1 loci,
both located in human chromosome 6p21-22, are among
the highly induced genes. These data, on both gene speciﬁc
mechanisms and global transcriptome effects of HDACi
in a B-lymphoid cell background indicate that HDACi
-besides hindering tumor growth- can also boost MHC II
expression strengthening the host’s immune response. This
information can have important implications in future thera-
peutic strategies.
MATERIALS AND METHODS
Cell culture and reagents
HeLa cells were cultured in DMEM supplemented with 10%
heat-inactivated fetal bovine serum. Raji and RJ2.2.5 cells
were cultured in RPMI. IFNg (R&D) was used at a ﬁnal
concentration of 100 U/ml. Antibodies against acetylated
and methylated histones were from Upstate biotechnology;
TBP, RNA polymerase II, CBP and GCN5 from Santa Cruz
Biotechnology; and RFX5, NFY-A from Rockland Immuno-
chemicals.
Plasmids, transfections and flow cytometry
The MHC II gene promoter was cloned upstream of the luci-
ferase coding sequence in the pGL3-basic vector (Promega).
Lymphoma cells were electroporated using the BioRad Gene
Pulser electroporator at 0.23 kV and 960 mF.
RT-PCR and ChIPs
RNA was prepared with the Trizol reagent (Gibco-BRL). RT
reactions were performed with MMLV from Finnzymes.
ChIPs were performed according to the protocol descri-
bed previously (6). For real-time PCR, we used SYBR
Green I and the Opticon Monitor system from MJ
Research. Primers for RT–PCR and ChIP are indicated in
the Supplementary data.
Detailed description of the FRAP and Affymetrix
microarray analysis protocols are included in the
Supplementary data.
RESULTS
The MHC II enhancer determines transcriptional
induction by TSA
To study the mechanism of transcriptional activation of the
MHC II DRA gene in a CIITA independent manner, we used
the HDAC inhibitor TSA. Total RNA from RJ225 cells that
are defective in CIITA synthesis (17) was analyzed using
quantitative RT–PCR. Figure 1A (black bars) shows a signi-
ﬁcant increase of DRA gene transcription which occurs within
2 h after TSA addition and increases continuously up to 12 h
post-treatment in an agreement with an earlier report (18). For
comparison, we examined in parallel the expression of the p53
tumor suppressor gene shown to be suppressed by TSA (19).
Quantitative RT–PCR analysis conﬁrms that p53 is down
regulated by TSA treatment in RJ225 but not in HeLa cells
(Figure 1B). For comparison, the levels of GAPDH remained
unaffected in both cell types (Figure 1C). To investigate
whether induction of DRA was regulated at the transcriptional
level, we applied TSA to RJ225 cells pre-treated with
Figure 1. Effects of Trichostatin on gene expression. Real-time RT–PCR at
varioustimepointsafter200nMTSAtreatmentofHeLaandRJ225cellsshows
inductionofDRA(A)reductionofp53(B)andnochangeofGAPDH(C)RNA.
The expression levelsatthe zerohourstimepointis setto one.TheRNAlevels
after 12 h of interferon-g treatment in HeLa cells and wt Raji are shown for
comparison. Actinomycin D reduces the GAPDH (E) RNA levels and blocks
TSAinductionofDRA(D).TheXandYboxelementsoftheMHCIIenhancer
are important for TSA response (F). Cells were transiently transfected with the
indicated wild type (wt) class II promoter–Luciferase fusion or its isogenic
derivativesthatcarryamutatedXorYbox (mX,mY)orboth(mXY).Dataare
averages of 3–5 experiments showing the ratio of TSA treated for 24 h over
untreated RJ225 cells.
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RT–PCR (Figure 1E) showed that TSA-mediated induction of
DRA requires new RNA synthesis and does not involve post-
transcriptional mechanisms (Figure 1D). To examine the cell
type speciﬁcity of the TSA-mediated induction of MHC II
transcription, we tested whether TSA could upregulate
MHC II transcription in HeLa cells. In this cell type, MHC
II genes are silent and can be induced by IFNg treatment that
stimulates CIITA synthesis. As opposed to RJ225 cells, DRA
gene expression was not induced in HeLa cells (Figure 1A) at
comparable or even higher TSA concentrations (400 nM or
1 mM, data not shown). The functional signiﬁcance of these
results was further shown by demonstrating the ability of TSA
to induce surface expression of DR protein as measured by
ﬂow cytometry (Supplementary Figure S1) in agreement with
the RT–PCR data.
Both the constitutive and inducible expression of MHC II
genes require the presence of an intact proximal enhancer that
consists of three conserved cis-regulatory elements, the S, X
and Y boxes (3). To determine the requirement of distinct
MHC II cis-regulatory elements for TSA induction, we
used MHC II promoter–luciferase gene fusions. Luciferase
activity was determined in transient transfection experiments
into RJ225 cells treated or untreated with TSA. Figure 1F
shows that addition of 200 nM TSA strongly induced the
activity of the promoter that carries an intact enhancer in
RJ225. An enhancer with disrupted X box (mX) retained
only 20% of the intact enhancer inducibility to TSA. Disrup-
tion of the Y box (mY) or elimination of both X and Y boxes
(mXY) led to almost complete elimination of responsiveness
to TSA (Figure 1F). The signiﬁcance of the CCAAT or Y box
in mediating a positive response to TSA has been shown in the
case of Gdf11 gene (20). These results indicate that the effect
of TSA on the DRA gene is mediated through both X and Y
boxes that are required for the MHC II enhanceosome assem-
bly. Overall these data demonstrate that TSA rescues MHC II
surface expression in a cell type and enhanceosome speciﬁc
manner.
TSA-induced changes of histone modifications
TSA treatment induces high levels of bulk histone acetylations
in RJ225, Raji and, to a lesser extend, HeLa cells (Supple-
mentary Figure S2). To study the occupancy of the DRA Class
II promoter by HDAC and HATs, we used ChIP assays.
Figure 2A and B show that at the silent state, the DRA pro-
moter binds HDAC1 and HDAC2. Two hours following TSA
treatment, HDAC1 levels on the DRA promoter were reduced
to 50% of the control and remained stable over the course of
monitoring (Figure 2A) whereas HDAC2 showed even higher
decrease to 20% of the control (Figure 2B). In order to deter-
mine which factors are involved in promoter recruitment of
HDACs, we examined the interaction of HDAC1 with the
enhanceosome factors. Supplementary Figure S3 shows that
among the known seven class II enhanceosome factors RFX5
and RFX-AP strongly interact with HDAC1. RFX-ANK and
CREB show weak interaction whereas the NFY subunits do
not interact at all.
We further examined the recruitment of the HAT coactiv-
ators CBP and GCN5, known to be involved in the CIITA
mediated DRA gene transcription (6). The DRA promoter
contains low levels of CBP and GCN5 in RJ225 cells
(Figure 2C and D) that do not signiﬁcantly change after
TSA. Therefore, we conclude that pre-existing HATs on the
silent DRA promoter are sufﬁcientto lead fast tohyperacetyla-
tion after inhibition of HDAC activity.
To monitor the status of histone modiﬁcations in the DRA
promoter following TSA treatment, we analyzed the histone
H3 and H4 acetylation levels using anti-acetylated H3 (acK9
and K14) and anti-acetylated H4 (acK5, K8, K12 and K16)
antibodies. In RJ225 cells, the DRA promoter contains very
low levels of acetylated H3 (Figure 3A) and acetylated H4
Figure 2. Promoter associated HATs and DACs on the DRA and p53 genes. Chromatin immunoprecipitates with anti-HDAC1 (A and E), anti-HDAC2 (B and F),
anti-CBP(CandG) oranti-GCN5 (DandH) antibodiesweresubjectedto real-timePCRusingprimersforDRA(A,B,C,D)orp53 (E,F,G,H)promoters.Thelevels
of untreated Raji cells are shown for comparison. Results represent averages of 3 experiments with their error bars and are expressed as % of the input chromatin
that was set at 5% of the amount used for immunoprecipitation.
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histone acetylation (up to 30-fold) were detected in the DRA
promoter at levels comparable to the parental Raji cells. The
histone acetylation of the DRA promoter in HeLa cells was not
inﬂuenced by TSA (Figure 3A). H4 acetylation of the DRA
promoter showed a 6–9-fold increase in RJ225 cells upon TSA
treatment (Figure 4B). Histone acetylation of the GAPDH
promoter showed small gradual decrease over the time course
of these experiments (data not shown). Thus TSA causes a
dramatic increase in histone H3 acetylation and a lower
increase in histone H4 acetylation of the DRA promoter in
RJ2.2.5 cells.
To correlate the gene response to TSA with histone modi-
ﬁcation marks, we examined the dynamics of histone methyla-
tion following TSA treatment. Figure 3C shows that
signiﬁcant levels of histone H3 dimethylated at K4 (dimK4)
reside at both the transcriptionally silent (RJ225 cells) and the
active (Raji cells) DRA promoters. High histone H3-K4
dimethylation has been linked to a permissive chromatin
state that is either active or potentially active (21,22). Accord-
ingly, TSA treatment increased H3 dimK4 levels at the
inducible DRA promoter as opposed to the situation observed
on the repressed p53 promoter (Figure 3G). Conversely,
histone H3-K9 dimethylation (dimK9), a modiﬁcation that
marks silent euchromatin (23,24), was increased in the
transcriptionally silent DRA promoter in RJ225 cells relative
tothetranscriptionallyactiveDRA promoterinRajicells. This
histone modiﬁcation was progressively reduced during the
course of TSA induction in RJ225 cells (Figure 3D).
Promoter recruitment of transcription factors by TSA
The RJ225 line contains a truncated form of CIITA that is
detectable at the RNA level (17) but it is unclear whether any
truncated protein is detectable in RJ225 cell extracts. Earlier
studies with ChIP showed that such a truncated protein cannot
be recruited to the promoter (5). To eliminate the possibility
that TSA may result to the recruitment of the truncated CIITA
to the DRA promoter, we performed experiments outlined in
Supplementary Figure S4.
To determine whether TSA affects the promoter bound
MHC enhanceosome, we monitored the binding of the
RFX5 and NFY-A factors. Figure 4C and D, show high occu-
pancy by both RFX5 and NFY-A in TSA untreated RJ225
cells. Upon TSA treatment a 2-fold increase of the binding
of those factors was observed in responder RJ225 but not in
non-responder HeLa cells (Figure 4C). This effect is also
observed in interferon g treated HeLa cells (11), indicating
that the TSA-mediated class II enhanceosome stabilization is
functionally connected to its transcriptional action.
Finally, we examined the effect of TSA on the recruitment
of the general transcription machinery (GTM). We observed
an early increase of TBP recruitment (Figure 4A) and higher
occupancy by RNA PolII (Figure 4B) on the DRA promoter.
Contrary to this, TSA reduced PolII occupancy on the p53
promoter (Figure 4F).
Therefore, the TSA-induced changes of histone modiﬁca-
tion and the recruitment of the GTM correlate with the gene
speciﬁc transcriptional effect.
TSA affects HDAC and RFX5 protein mobilities
To study whether promoter ChIP results correlate with the
global properties of HDACs or the enhanceosome factors,
we investigated the relative mobilities of HDAC1, HDAC2
and RFX5 in RJ225 cells using ﬂuorescence recovery after
photobleaching (FRAP) experiments. Figure 5 shows the
recovery curves obtained after photobleaching of green ﬂuor-
escent protein (GFP)-fused DACs or RFX5 in the nucleus.
TSA treatment signiﬁcantly increases the recovery rate of
either HDAC1 (half recovery time 1 versus 3 s of the
untreated) or HDAC2 (half recovery time 1.5 versus 3.7 s
of the untreated) (Figure 5A and B) whereas that of RFX5
decreases (half recovery time 9 versus <1.5 s of the untreated)
Figure 3. Promoter associated histone acetylation and methylation levels correlate with gene induction or repression. Chromatin from the indicated cells was
immunoprecipitated with antibodies against acetyl H3 (A and E), acetyl H4 (B and F), anti-dimethyl H3-K4 (C and G) and anti-dimethyl H3-K9 (D and H) and
amplifiedbyreal-timePCRwithprimersfortheDRApromoter(A,B,C,D)andthep53promoter(E,F,G,H).ExperimentalprocedureandstatisticsareasinFigure2.
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factors correlates with that of the DRA promoter associated
proteins. High mobility of HDACs after TSA may result in
their reduced DRA promoter occupancy. Conversely, the
decrease of the RFX5 mobility by TSA is consistent with
stabilization of the enhanceosome on the DRA promoter.
The TSA-elicited gene expression program in RJ2.2.5
We next asked what are the genome-wide consequences of
applying TSA to the RJ225 cells. This analysis aimed to: (i)
detect how the other MHC locus members respond to epigen-
etic modiﬁcations; (ii) identify genes that are co-regulated
with MHC II that might be involved in class II gene induction
or function; and (iii) assess the transcriptome effects TSA
besides rescue of MHC II gene expression. To this end,
RJ225 cells untreated or treated with 200 nM TSA for 4
and 12 h were proﬁled by probing the human Affymetrix
GeneChip U133A array containing 22000 probe sets. The
complete list of TSA-regulated genes (Supplementary
Table S1) along with relevant information are provided in
the Supplementary data.
This analysis shows that 260 genes responded to TSA treat-
ment in a positive (156 genes) or negative (104 genes) manner
at the 3-fold level. Many up-regulated genes fall into two
major groups: genes involved in cell defence mechanisms
(interferon or virus regulated, pro-inﬂammatory or apoptotic
pathways, immune response) and genes of the histone family.
Interestingly, the MHC class I and II genes and the great
majority of the histone genes are located on the Chromosome
6p21-22 (Table 1) suggesting a clustering of HDAC-sensitive,
common gene regulatory mechanisms and/or TSA-mediated
long range chromatin changes. Figure 6 shows that the MHC
class I genes were minimally up-regulated. Concerning MHC
II genes, in addition to the highly induced DRA gene, the DRB
and DPB genes showed also strong induction whereas the
DQA, DQB, DPA, DPB, DMA and DMB were induced at
a lower (2–4-fold) level. In contrast, the DO genes that
produce molecules antagonistic to the action of DM for
CLIP-antigenic peptide replacement (25) showed a distinct
response: The DOA gene showed 2-fold increase whereas
the DOB gene that has unusually high basal levels relative
to the other MHC II members (26) was slightly reduced (70%
of the control). Thus TSA enhances antigen presentation
Figure 4. Enhanced recruitment of enhanceosome and general transcription components correlate with responsiveness to TSA. ChIP with antibodies against
TBP (A and E) and the large subunit of Pol II (B and F) were amplified by real-time PCR with DRA (A and B,) and p53 (E and F) primers from the indicated cells
and time points as in Figure 3. The RFX5 in RJ2.2.5 and HeLa (C) and NFY-A (D) enhanceosome components monitored on the DRA promoter during the TSA
time course.
Figure 5. Divergent effects of TSA on the nuclear mobility of HDAC1, HDAC2 and RFX5. RJ225 cells were transfected with the corresponding GFP fusion
constructsof HDAC1(A),HDAC2 (B) andRFX5 (C) andculturedwithoutor in the presenceof 200 nM TSA for18 h asindicated.The graphsshow representative
fluorescence recovery curves of the bleached areas in the nucleus over the shown time course (in seconds). The results are percentages of the postbleach over the
prebleach intensities after correction for background and fluorescent decay during imaging. The error range was smaller than 20% of the mean values.
Nucleic Acids Research, 2006, Vol. 34, No. 3 769functions without affecting the expression of negatively acting
non-classical MHC II genes.
DISCUSSION
HDAC inhibition is a strong modulator of the expression pat-
tern of many cellular genes that has multiple therapeutic
applications (27). In this report we have studied the molecular
mechanism of gene induction by TSA at both a gene speciﬁc
andgenome-widelevel.Wedeterminedthesequenceofevents
that are required for the TSA-induced transcription of the
MHC II gene DRA in the B cell type RJ225 that is lacking
the master regulator CIITA.
We show that in RJ225 cells, the DRA gene is suppressed
viarepressive histone modiﬁcations suchashistone H3and H4
hypoacetylations and H3-K9 dimethylation. In the absence of
the master coactivator CIITA, the class II enhanceosome is
recruiting considerable amounts of HDACs and low amounts
of HAT proteins. On the promoter of DRA gene TSA induces
very rapid and strong histone acetylations on both H3 and H4
that are accompanied by an increase of histone H3 dimethyl-
ated K4 and a reduction of histone H3 dimethylated K9. A
similar synergy in gene repression between histone deacetyla-
tion and K9 methylation was recently reported in the Xenopus
oocyte system (28).
In correlation with the histone modiﬁcations, we found that
TSA increases the intranuclear mobility of HDAC 1 and 2 in
RJ225 cells. This effect can account for the reduction of the
amount of HDACs residing on the promoter of DRA following
TSA addition. As a consequence, acetylation of the promoter
rises without an increase in the recruitment of HAT type
cofactors. Contrary to its effects on HDACs, TSA affects
the mobility of the class II enhanceosome factor RFX5 in
the opposite way. This may be the basis of the higher DRA
promoter occupancy observed by the ChIP experiments. We
conclude that the effects of TSA on HDAC depletion and
inhibition that permit chromatin hyperacetylation, in combina-
tion with enhanceosome stabilization, are sufﬁcient to attract
the transcription machinery and allow DRA expression.
We show that TSA induces DRA gene transcription in a B
cell environment but not in HeLa cells. This selectivity of
TSA-regulated transcription may reﬂect differences in chro-
matin environments. For instance, the DRA gene in B cells
may be in a chromatin state permissive to the effect of TSA,
whereas in HeLa cells the same gene may reside in a refractory
chromatin structure. Restriction site accessibility studies using
B-lymphoid and HeLa cells support this assumption (29).
Surprisingly, in spite of its non selective DAC inhibition,
the TSA-elicited gene program in this B cell leukemia model
has very little overlap with similar studies in other cell types,
suggesting that its transcriptome-wide responses are highly
cell type speciﬁc. In our system, TSA globally rescues
MHC II expression in the absence of CIITA and upregulates
many histone members that reside in the 6p21 chromosomal
region. Many other up-regulated genes in this system are part
of general and immune speciﬁc defences.
Inspection of the genes differentially regulated by CIITA
(30) and TSA (this study) in RJ225 cells reveals that besides
the MHC II, only two other genes, tubulin beta and PEG10 are
in common. It is thus likely that tubulin beta and PEG10 share
common regulatory mechanisms with MHC II genes.
Growing evidence positively correlates expression of MHC
II with cancer cell differentiation or prognosis (31,32) and
epigenetic inactivation of CIITA expression is found in
tumor lines or cancer tissue. These results suggest that
up-regulation of MHC II may be beneﬁcial in cancer and
are in agreement with the proposed importance of MHC II
molecules in tumor-antigen recognition and the generation of
an anti-tumor immune response. Indeed in recent studies
exogenous CIITA has been used in a gene therapy approach
to restore MHC II and/or tumor immune-resistance (33,34).
We show here that global up-regulation of MHC II genes in
a CIITA deﬁcient environment can also be achieved by an
epigenetic modiﬁer. Recent studies emphasize the cell cycle
arrest and apoptotic properties of HDACi to justify their use in
cancer therapy and ongoing clinical trials. Indeed recent
Table 1. Genes on Chr.6p21 with modified expression upon TSA treatment
Gene names Maximum fold change
HLA-DRA 11.7 ± 1.9
HLA-DRB1 5.9 ± 1.3
HLA-DPB1 4.4 ± 1.2
HLA-DRB3 4.0 ± 1
H3 member K 10.2 ± 0.6
H1 member 2 9.8 ± 1.3
H2B member A 17.1 ± 5.2
H2A member L 6.5 ± 1.7
H2A member P 6.5 ± 1.7
H2B member B 5.1 ± 0.2
H2B member J 5.1 ± 0.2
H2B member T 4.9 ± 0.3
H2B member L 4.8 ± 1.6
H2B member H 4.6 ± 0.3
H2B member G 3.7 ± 0.3
H2B member K 3.2 ± 0.3
Tubulin beta polypeptide 7.2 ± 1.6
Sialidase 1 (lysosomal sialidase) 7.2 ± 2.7
Immediate early response 3 4.4 ± 1.6
Tumor necrosis factor
(TNF superfamily, member 2)
3.6 ± 0.1
Lymphotoxin alpha (TNF superfamily, member 1) 0.2 ± 0.1
Transcription factor EB 0.3 ± 0.04
Maximum fold change with standard deviation for the genes on chromosome
6p21 at either 4 or 12 h of TSA treatment relative to the untreated control are
shown.
Figure 6. MHC locus response to TSA. Affymetrix analysis data from RJ225
cells cultured without or in the presence of 200 nM TSA for 4 and 12 h. The
graphshowsaveragefoldinductionwiththeircorrespondingerrorbarsat4and
12 h after TSA of the various MHC genes represented in the array.
770 Nucleic Acids Research, 2006, Vol. 34, No. 3observations show that TSA induces the ability of antigen
presentation and anti-tumor immunity (35–37). Our results
extend the rational basis for using HDACi in cancer treatment
by demonstrating the up-regulation of many host defence
genes including MHC II genes that are positively involved
in tumor-antigen immune presentation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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